News from Daiichi Sankyo, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 04, 2017, 08:00 ET Daiichi Sankyo, Inc. Announces Commitments in Pain Care Program Focused on Responsible Pain Management

Daiichi Sankyo, Inc. today announced the establishment of Commitments in Pain Care, a program focused on education and awareness about responsible...


Sep 06, 2017, 08:30 ET Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers

Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) and Sanford Burnham Prebys Medical Discovery Institute (SBP) announced the start of a...


May 30, 2017, 08:00 ET Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC (Inspirion) announced today that Daiichi Sankyo will lead the U.S. commercialization of...


Mar 13, 2017, 08:00 ET Daiichi Sankyo, Inc. Announces New Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at the ACC 66th Annual Scientific Session

Daiichi Sankyo, Inc., (hereafter, Daiichi Sankyo) today announced the presentation of five abstracts at the American College of Cardiology's (ACC)...


Mar 06, 2017, 08:00 ET Daiichi Sankyo, Inc. Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting

Daiichi Sankyo Company, Inc. (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ENTRUST-AF PCI study....


Nov 07, 2016, 08:00 ET Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

Daiichi Sankyo, Inc., (hereafter, Daiichi Sankyo) today announced the presentation of six abstracts at the American Heart Association (AHA)...


Oct 25, 2016, 09:00 ET Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond™ Formulated with SentryBond™ Abuse-Deterrent Technology

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC (Inspirion) announced today that the companies have entered into a strategic collaboration...


Sep 06, 2016, 09:00 ET Daiichi Sankyo Announces New Global Head of Development

 Daiichi Sankyo, Inc. today announced the appointment of Marielle Cohard-Radice, MD as Executive Vice President, Global Head of Development,...


Aug 24, 2016, 08:00 ET Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

 Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) today announced the presentation of 13 abstracts at the ESC Congress 2016, taking place from...


Aug 23, 2016, 09:00 ET Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group

 Daiichi Sankyo, Inc. ("the Company") announced today that Leigh Ann Errico has joined Daiichi Sankyo, Inc. as the Company's Vice President of...


Apr 18, 2016, 10:31 ET Daiichi Sankyo, Inc. To Establish New U.S. Headquarters in Basking Ridge, New Jersey

 Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., today announced that it will establish a new U.S. headquarters,...


Nov 10, 2015, 16:11 ET Daiichi Sankyo and Plexxikon Announce FDA Approval of Cobimetinib in Combination with Zelboraf® (vemurafenib) in Advanced Melanoma

 Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced the U.S. Food and Drug Administration (FDA)...


Oct 30, 2015, 11:23 ET FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Plexxikon's Investigational CSF-1R Inhibitor Pexidartinib (PLX3397) in Tenosynovial Giant Cell Tumor

 Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that the U.S. Food and Drug Administration...


Oct 16, 2015, 11:11 ET Daiichi Sankyo, Inc. Reorganizes its U.S. Commercial Operations to Support Upcoming Specialty Pipeline

Daiichi Sankyo, Inc. ("the Company") announced today that it will reorganize its U.S. Commercial organization as it begins to transition from a...


Mar 19, 2015, 06:00 ET Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US

 Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US, in line with...


Jan 09, 2015, 10:09 ET Daiichi Sankyo, Inc. Announces Civil Settlement

Daiichi Sankyo, Inc. ("the Company") announced today that it has reached a civil settlement with the U.S. Government, as...


Dec 04, 2014, 16:40 ET Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and...


Aug 06, 2014, 19:00 ET Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US

Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have...


Apr 18, 2014, 09:00 ET Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.

 Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States...


Jan 08, 2014, 08:30 ET Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly...


Oct 03, 2013, 16:00 ET Daiichi Sankyo, Inc. Makes Two New Executive Appointments

 Daiichi Sankyo, Inc. today announced that Glenn Gormley, MD, PhD, has been named corporate President and Chairman of Daiichi Sankyo, Inc....


Jun 06, 2013, 08:00 ET New Guidelines From the American Association of Clinical Endocrinologists (AACE) Identify Welchol® (colesevelam HCI) for Lowering Both A1C and LDL-Cholesterol in Patients with Type 2 Diabetes

Recent guidance from the American Association of Clinical Endocrinologists (AACE) highlight for the first time a cardiovascular risk factor...


Mar 27, 2012, 10:30 ET Centennial Tree Planting Ceremony Commemorates Philanthropy, Collaboration and Friendship

Today, chief executives from Daiichi Sankyo joined the National Cherry Blossom Festival and American and Japanese dignitaries in Washington,...


Mar 09, 2012, 08:00 ET Chef Becker Announces Franklin's Family Fixin's Contest Winner

Chef Franklin Becker of the Two Reasons, One Recipe campaign is pleased to name Lorin Cook of Alpine, N.J. the grand prize winner of the Franklin's...


Oct 21, 2011, 11:45 ET Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey

Approximately 100 cherry tree saplings were planted in Central Park of Morris County today, the newest park in the Morris County Park System,...